ODM-104 + levodopa MR + carbidopa

**ODM-104 + levodopa MR + carbidopa** is a triple combination therapy under clinical development for the treatment of Parkinson's disease, especially for patients experiencing motor fluctuations and "wearing-off" symptoms. - **ODM-104** is a novel, potent catechol-O-methyltransferase (COMT) inhibitor developed to improve and stabilize levodopa pharmacokinetics compared to standard COMT inhibitors like entacapone. - **Levodopa MR** (modified-release levodopa) is a dopamine precursor replacing depleted dopamine in the brain, mitigating Parkinsonian motor symptoms. - **Carbidopa** is an aromatic L-amino acid decarboxylase (AADC) inhibitor that prevents peripheral breakdown of levodopa, increasing its availability to the CNS. The therapeutic rationale is that simultaneous administration of MR levodopa, carbidopa, and strong COMT inhibition (ODM-104) achieves more stable and sustained levodopa concentrations, potentially reducing motor fluctuations and improving clinical control without significantly raising peak plasma concentrations[2][4][8].